Stockhead’s Ashtyn Hiron sits down with Paradigm Biopharmaceuticals (ASX:PAR) managing director Paul Rennie to close the books on 2023 and gain a sneak peek into what’s around the corner this year.

Paradigm Biopharmaceuticals’s primary focus is the development of injectable pentosan polysulfate sodium (iPPS/Zilosul®), for the treatment of osteoarthritis (OA).

“We would hope that we are qualified for the provisional approval pathway and if we do we could see the product on the Australian market as early as June 2025,” said Rennie.

Tune in to hear what’s coming up for Paradigm Biopharmaceuticals in 2024.

Read MoreHealth

Featured Companies

You might be interested in